Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV‐1‐infected subjects with dyslipidaemia-Reference-Cited by-同舟云学术

Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV‐1‐infected subjects with dyslipidaemia

Published:2017-07-03 Issue:10 Volume:18 Page:782-786
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Echeverría P¹²,Bonjoch A¹²,Puig J¹²,Ornella A¹³,Clotet B¹²⁴⁵,Negredo E¹²⁵

Affiliation:

1. Foundation Lluita against AIDS University Hospital Germans Trias i Pujol Badalona Spain

2. Statistics and Operations Research Technical University of Catalonia Barcelona 08020 Spain

3. Autonomous University of Barcelona Catalonia Spain

4. AIDS Research Institute‐IRSICAIXA Institute Germans Trias I Pujol (IGTP) University Hospital Germans Trias i Pujol Badalona Spain

5. University of Vic – Central University of Catalonia UVic‐UCC Department of Internal Medicine Vic Spain

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.12530

Reference20 articles.

1. Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV‐1‐infected adults and adolescents. April2015. Department of Health and Human Services.http://aidsinfo.nih.gov/contentfiles.

2. Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus Infection

3. Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance

4. Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers

5. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial;The Lancet Regional Health - Western Pacific;2024-08

2. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study;Open Forum Infectious Diseases;2024-04-26

3. Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure;Drug Design, Development and Therapy;2024-04

4. Effects of Continuous Pharmacist Interventions Based on Shared Decision-Making in Outpatient Care for People with Human Immunodeficiency Virus;Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences);2023-02-10

5. Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus;Medicine;2022-12-09